PDS Biotechnology Secures Key Patent Strengthening PDS0101 Protection

PDS Biotechnology ( (PDSB) ) has shared an announcement.

On January 22, 2026, PDS Biotechnology announced that the U.S. Patent Office issued a Notice of Allowance for a new U.S. patent covering technology underlying its lead asset PDS0101, a cancer immunotherapy based on the company’s Versamune platform. The patent, titled “Methods and Compositions Comprising Cationic Lipids for Stimulating Type I Interferon Genes,” will provide broad composition and method-of-use claims and strengthens PDS Biotech’s intellectual property estate, which already includes patents across major markets including the U.S., Europe, Japan, China, Australia, Canada, Israel, Mexico, and Hong Kong. Together with anticipated U.S. biologics exclusivity, the patent is expected to secure roughly 20 years of market protection for PDS0101, which is being tested in the Phase 3 VERSATILE-003 trial in HPV16-positive head and neck cancers. The company has also submitted an FDA protocol amendment for this pivotal trial to make progression-free survival the earlier-evaluable primary endpoint for accelerated approval, while median overall survival remains the primary endpoint for full approval, potentially sharpening PDS Biotech’s path to market and reinforcing its competitive positioning in oncology immunotherapies.

The most recent analyst rating on (PDSB) stock is a Hold with a $0.93 price target. To see the full list of analyst forecasts on PDS Biotechnology stock, see the PDSB Stock Forecast page.

Spark’s Take on PDSB Stock

According to Spark, TipRanks’ AI Analyst, PDSB is a Neutral.

The score is held down primarily by weak financial performance (no revenue, ongoing losses, substantial cash burn, and a reduced equity base versus debt). Partially offsetting this are moderately improving technical momentum and generally positive clinical/regulatory updates from the earnings call and recent corporate events, though funding and trial-timing risks remain key.

To see Spark’s full report on PDSB stock, click here.

More about PDS Biotechnology

PDS Biotechnology Corporation is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers. The company is advancing its lead investigational targeted immunotherapy PDS0101 (Versamune® HPV) for advanced HPV16-positive head and neck squamous cell cancers, in combination with standard-of-care immune checkpoint inhibitors and, in some settings, with its IL-12 fused antibody-drug conjugate PDS01ADC.

Average Trading Volume: 865,542

Technical Sentiment Signal: Sell

Current Market Cap: $51.77M

See more insights into PDSB stock on TipRanks’ Stock Analysis page.